Global Cancer Technology is a non-revenue biopharma company developing a novel treatment for cancers. We are developing a small molecule PI3K inhibitor that can cross the blood-brain barrier and has shown great promise in preclinical cell and animal studies as a potential glioblastoma therapy.
Glioblastoma Multiforme (GBM) is the most common form of brain cancer with an incidence rate of 3.21 per 100,000 population.
It is also the most malignant and aggressive form of brain tumor.
Most GBM’s have strong drug resistance against the PI3K/AKT/mTOR inhibitors due to the cytoprotective effect and the adaptive response of autophagy during the treatment.
Standard GBM treatments are toxic and associated with poor prognosis.
OUR Solution: GCT-007
A unique, mechanistically distinct dual inhibitor targeting both the PI3K and mTOR pathways.
GCT-007 has thus far proven to:
Research takes time and money. Bringing a drug to market now costs an average of $ 1.3 Billion and can take up to a decade in time. It is extremely challenging and with less funding, it can take even longer. Yet the potential to change lives makes it an attractive pursuit despite the complexity and risks.